• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Hematological Cancers Drug Pipeline Update 2015

  • ID: 1197061
  • June 2015
  • Region: Global
  • Bioseeker

Unmet needs across the hematological malignancies remain high, with most traditional therapies conferring low levels of specificity and high toxicity.
There are today 618 companies plus partners developing 950 hematological cancer drugs in 2254 developmental projects in cancer. In addition, there are 10 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 295 drugs. Hematological Cancers Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 451 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 432 out of the 436 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 75 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.

How May Drug Pipeline Update Be of Use?

- Show investors/board/management READ MORE >

Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)